Literature DB >> 8611429

A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model.

A Orenstein1, G Kostenich, L Roitman, Y Shechtman, Y Kopolovic, B Ehrenberg, Z Malik.   

Abstract

An in vivo study of tissue distribution kinetics and photodynamic therapy (PDT) using 5-aminolaevulinic acid (ALA), chlorin e6 (Chl) and Photofrin (PII) was performed to evaluate the selectivity of porphyrin accumulation and tissue damage effects in a tumour model compared with normal tissue. C26 colon carcinoma of mice transplanted to the foot was used as a model for selectivity assessment. Fluorescence measurements of porphyrin accumulation in the foot bearing the tumour and in the normal foot were performed by the laser-induced fluorescence (LIF) system. A new high-intensity pulsed light delivery system (HIPLS) was used for simultaneous irradiation of both feet by light in the range of 600-800 nm, with light doses from 120 to 300 J cm-2 (0.6 J cm-2 per pulse, 1 Hz). Photoirradiation was carried out 1 h after injection of ALA, 3 h after injection of Chl and 24 h after injection of PII. A ratio of porphyrin accumulation in tumour vs normal tissue was used as an index of accumulation selectivity for each agent. PDT selectivity was determined from the regression analysis of normal and tumour tissue responses to PDT as a function of the applied light dose. A normal tissue damage index was defined at various values (50, 80 and 100%) of antitumour effect. The results of the LIF measurements revealed different patterns of fluorescence intensity in tumour and normal tissues for ALA-induced protoporphyrin IX (ALA-PpIX), Chl and PII. The results of PDT demonstrated the differences in both anti-tumour efficiency and normal tissue damage for the agents used. The selectivity of porphyrin accumulation in the tumour at the time of photoirradiation, as obtained by the LIF measurements, was in the order ALA-PpIX > Chl > PII. PDT selectivity at an equal value of anti-tumour effect was in the order Chl > ALA-PpIX > PII. Histological examination revealed certain differences in structural changes of normal skin after PDT with the agents tested. The results of PDT selectivity assessment with respect to differences in mechanisms of action for ALA, Chl and PII are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611429      PMCID: PMC2075833          DOI: 10.1038/bjc.1996.185

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion.

Authors:  V H Fingar; T J Wieman; S A Wiehle; P B Cerrito
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

2.  Clearance times of porphyrin derivatives from mice as measured by in vivo fluorescence spectroscopy.

Authors:  J C Kennedy; P Nadeau; Z J Petryka; R H Pottier; G Weagle
Journal:  Photochem Photobiol       Date:  1992-05       Impact factor: 3.421

Review 3.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy.

Authors:  J C Kennedy; R H Pottier
Journal:  J Photochem Photobiol B       Date:  1992-07-30       Impact factor: 6.252

4.  Sensitivity of different rat tumour strains to photodynamic treatment with chlorin e6.

Authors:  G A Kostenich; I N Zhuravkin; A V Furmanchuk; E A Zhavrid
Journal:  J Photochem Photobiol B       Date:  1993-02       Impact factor: 6.252

5.  Photosensitizing properties of mono-L-aspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors.

Authors:  J D Spikes; J C Bommer
Journal:  J Photochem Photobiol B       Date:  1993-02       Impact factor: 6.252

6.  Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolevulinic acid in mice bearing mammary carcinoma.

Authors:  Q Peng; J Moan; T Warloe; J M Nesland; C Rimington
Journal:  Int J Cancer       Date:  1992-09-30       Impact factor: 7.396

7.  Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation.

Authors:  K Svanberg; T Andersson; D Killander; I Wang; U Stenram; S Andersson-Engels; R Berg; J Johansson; S Svanberg
Journal:  Br J Dermatol       Date:  1994-06       Impact factor: 9.302

8.  Experimental grounds for using chlorin e6 in the photodynamic therapy of malignant tumors.

Authors:  G A Kostenich; I N Zhuravkin; E A Zhavrid
Journal:  J Photochem Photobiol B       Date:  1994-03       Impact factor: 6.252

9.  Pharmacokinetics of a fluorescent drug using laser-induced fluorescence.

Authors:  J K Frisoli; E G Tudor; T J Flotte; T Hasan; T F Deutsch; K T Schomacker
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

10.  Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer.

Authors:  F Cairnduff; M R Stringer; E J Hudson; D V Ash; S B Brown
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more
  18 in total

1.  Effects of chlorin e6-mediated photodynamic therapy on human colon cancer SW480 cells.

Authors:  Yuhua Li; Yalu Yu; Ling Kang; Ying Lu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Laparoscopic fluorescence diagnosis for intraabdominal fluorescence targeting of peritoneal carcinosis experimental studies.

Authors:  Johannes Gahlen; Ruediger L Prosst; Matthias Pietschmann; Thomas Haase; Markus Rheinwald; Gisela Skopp; Josef Stern; Christian Herfarth
Journal:  Ann Surg       Date:  2002-02       Impact factor: 12.969

3.  A theoretical formalism for aggregation of peroxidized lipids and plasma membrane stability during photolysis.

Authors:  N A Busch; M L Yarmush; M Toner
Journal:  Biophys J       Date:  1998-12       Impact factor: 4.033

4.  Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization.

Authors:  Ana P Castano; Tatiana N Demidova; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2004-12       Impact factor: 3.631

Review 5.  Photodynamic therapy: one step ahead with self-assembled nanoparticles.

Authors:  Pinar Avci; S Sibel Erdem; Michael R Hamblin
Journal:  J Biomed Nanotechnol       Date:  2014-09       Impact factor: 4.099

6.  Ferritin nanocages to encapsulate and deliver photosensitizers for efficient photodynamic therapy against cancer.

Authors:  Zipeng Zhen; Wei Tang; Cunlan Guo; Hongmin Chen; Xin Lin; Gang Liu; Baowei Fei; Xiaoyuan Chen; Binqian Xu; Jin Xie
Journal:  ACS Nano       Date:  2013-07-11       Impact factor: 15.881

7.  Enhanced photodynamic efficacy and efficient delivery of Rose Bengal using nanostructured poly(amidoamine) dendrimers: potential application in photodynamic therapy of cancer.

Authors:  Krishnamoorthy Karthikeyan; Anish Babu; Sang-Jae Kim; Ramachandran Murugesan; Kadarkaraithangam Jeyasubramanian
Journal:  Cancer Nanotechnol       Date:  2011-08-13

8.  Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.

Authors:  Andrew Pye; Sandra Campbell; Alison Curnow
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-01       Impact factor: 4.553

Review 9.  Photodynamic therapy with fullerenes.

Authors:  Pawel Mroz; George P Tegos; Hariprasad Gali; Tim Wharton; Tadeusz Sarna; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2007-10-08       Impact factor: 3.982

10.  Porfimer-sodium (Photofrin-II) in combination with ionizing radiation inhibits tumor-initiating cell proliferation and improves glioblastoma treatment efficacy.

Authors:  Liat Benayoun; Moshe Schaffer; Rotem Bril; Svetlana Gingis-Velitski; Ehud Segal; Alexsander Nevelsky; Ronit Satchi-Fainaro; Yuval Shaked
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.